by Clinical Neuropsychologist Online | Thursday, August 13, 2026 | Dementia
Alzheimer’s &Dementia, Volume 22, Issue 8, August 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | August 13, 2026 Neuro-Dementia Previous...
by Clinical Neuropsychologist Online | Thursday, August 13, 2026 | Dementia
Abstract INTRODUCTION ABvac40 is an active immunotherapy targeting Aβ40, the main component of cerebrovascular deposition in Alzheimer’s disease (AD). A 24-month randomized, placebo-controlled phase 2 study (Part A) showed favorable safety and robust...
by Clinical Neuropsychologist Online | Wednesday, August 12, 2026 | Dementia
Abstract INTRODUCTION Cognitive decline may emerge in specific domains before overt dementia, yet domain-specific cognitive benefits of social engagement remain unclear. METHODS Using National Health and Aging Trends Study (NHATS) data (2011–2019) from 6,084...
by Clinical Neuropsychologist Online | Wednesday, August 12, 2026 | Dementia
Abstract INTRODUCTION The locus coeruleus (LC) is important in coordinating communication between brain regions through its widespread connections. However, the organization of its connections, and its changes with aging and Alzheimer’s disease (AD), remains...
by Clinical Neuropsychologist Online | Wednesday, August 12, 2026 | Dementia
Abstract INTRODUCTION Blood–brain barrier (BBB) dysfunction is an early feature of Alzheimer’s disease (AD). Fibrinogen represents a sensitive marker of BBB leakage, but whether it modifies longitudinal tau progression in cognitively unimpaired (CU) individuals...
by Clinical Neuropsychologist Online | Wednesday, August 12, 2026 | Dementia
Abstract INTRODUCTION Post mortem proteomic analysis of Alzheimer’s disease (AD) brain tissue has identified novel target genes and proteins for potential therapeutic development. Moesin (MSN) and CD44 were identified as candidate targets. Using human induced...
